Eloxx Pharmaceuticals Inc
Prices are adjusted according to historical splits.
Vitals
- Today's Low:
- $4.5859
- Today's High:
- $5.1
- Open Price:
- $4.85
- 52W Low:
- $1.6959
- 52W High:
- $19.2
- Prev. Close:
- $4.91
- Volume:
- 23027
Company Statistics
- Market Cap.:
- $14.51 million
- Book Value:
- -7.521
- Revenue TTM:
- $0
- Operating Margin TTM:
- 0%
- Gross Profit TTM:
- $0
- Profit Margin:
- 0%
- Return on Assets TTM:
- -71.21%
- Return on Equity TTM:
- -615.23%
Company Profile
Eloxx Pharmaceuticals Inc had its IPO on 2018-01-19 under the ticker symbol ELOX.
The company operates in the Healthcare sector and Biotechnology industry. Eloxx Pharmaceuticals Inc has a staff strength of 18 employees.
Stock update
Shares of Eloxx Pharmaceuticals Inc opened at $4.85 at the start of the last trading session i.e. 2023-09-12.
The stocks traded within a range of $4.59 - $5.1, and closed at $4.7.
This is a -4.28% slip from the previous day's closing price.
A total volume of 23,027 shares were traded at the close of the day’s session.
In the last one week, shares of Eloxx Pharmaceuticals Inc have slipped by -12.96%.
Eloxx Pharmaceuticals Inc's Key Ratios
Eloxx Pharmaceuticals Inc has a market cap of $14.51 million, indicating a price to book ratio of 6.3127 and a price to sales ratio of 0.
In the last 12-months Eloxx Pharmaceuticals Inc’s revenue was $0 with a gross profit of $0 and an EBITDA of $-28878000. The EBITDA ratio measures Eloxx Pharmaceuticals Inc's overall financial performance and is widely used to measure its profitability.
In the trailing 12-month period, Eloxx Pharmaceuticals Inc’s operating margin was 0% while its return on assets stood at -71.21% with a return of equity of -615.23%.
In Q1, Eloxx Pharmaceuticals Inc’s quarterly earnings growth was a positive 0% while revenue growth was a positive 0%.
Eloxx Pharmaceuticals Inc’s PE and PEG Ratio
- Forward PE
- 0
- Trailing PE
- 0
- PEG
Its diluted EPS in the last 12-months stands at $-14.68 per share while it has a forward price to earnings multiple of 0 and a PEG multiple of . A low price to earnings ratio can mean the stock is attractively valued while a high ratio suggests the stock may be overvalued.
The PEG on the other hand provides a broader view compared to the P/E ratio and gives greater insight into Eloxx Pharmaceuticals Inc’s profitability.
Eloxx Pharmaceuticals Inc stock is trading at a EV to sales ratio of 0 and a EV to EBITDA ratio of 0.1414. Its price to sales ratio in the trailing 12-months stood at 0.
Eloxx Pharmaceuticals Inc stock pays annual dividends of $0 per share, indicating a yield of 0% and a payout ratio of 0%.
Balance sheet and cash flow metrics
- Total Assets
- $7.20 million
- Total Liabilities
- $19.46 million
- Operating Cash Flow
- $0
- Capital Expenditure
- $0
- Dividend Payout Ratio
- 0%
Eloxx Pharmaceuticals Inc ended 2024 with $7.20 million in total assets and $0 in total liabilities. Its intangible assets were valued at $7.20 million while shareholder equity stood at $-16293000.00.
Eloxx Pharmaceuticals Inc ended 2024 with $0 in deferred long-term liabilities, $19.46 million in other current liabilities, 22000.00 in common stock, $-280618000.00 in retained earnings and $0 in goodwill. Its cash balance stood at $4.90 million and cash and short-term investments were $4.90 million. The company’s total short-term debt was $2,203,000 while long-term debt stood at $4.03 million.
Eloxx Pharmaceuticals Inc’s total current assets stands at $6.40 million while long-term investments were $0 and short-term investments were $0. Its net receivables were $0 compared to accounts payable of $2.43 million and inventory worth $0.
In 2024, Eloxx Pharmaceuticals Inc's operating cash flow was $0 while its capital expenditure stood at $0.
Comparatively, Eloxx Pharmaceuticals Inc paid $0 in dividends in 2024.
Other key metrics
- Current Trading Price
- $4.7
- 52-Week High
- $19.2
- 52-Week Low
- $1.6959
- Analyst Target Price
- $50
Eloxx Pharmaceuticals Inc stock is currently trading at $4.7 per share. It touched a 52-week high of $19.2 and a 52-week low of $19.2. Analysts tracking the stock have a 12-month average target price of $50.
Its 50-day moving average was $5.73 and 200-day moving average was $4.96 The short ratio stood at 0.06 indicating a short percent outstanding of 0%.
Around 68.4% of the company’s stock are held by insiders while 4396.7% are held by institutions.
Frequently Asked Questions About Eloxx Pharmaceuticals Inc
Similar Industry Stocks (Biotechnology)
Most Active
Top Gainers
Top Losers
About
Eloxx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing ribosome modulation for the treatment of rare and ultra-rare premature stop codon diseases. Its lead investigational drug product candidate is ELX-02, which is in Phase 2 clinical trial for the treatment of cystic fibrosis and nephropathic cystinosis patients with diagnosed nonsense mutations. The company also develops various preclinical programs for the treatment of alport syndrome, recessive dystrophic epidermolysis bullosa, junctional epidermolysis bullosa, and familial adenomatous polyposis, as well as various earlier discovery stage programs in oncology. Eloxx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Watertown, Massachusetts.